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ABSTRACT
PURPOSE: The objective of the present study was to determine the effectiveness of esomeprazole-based se-
quential therapy and Bio Gaya probiotic for the treatment of Helicobacter pylori-infection (Hp-infection) 
with associated gastroduodenal diseases.
MATERIAL AND METHODS: The study covered 104 patients with dominating upper dyspeptic syndrome 
and Hp-infection examined by means of two or more methods. Esomeprazole-based sequential therapy con-
sisted in amoxycillin in a dose of 1,0 g two times daily for the first five days followed by clarithromycin and 
metronidazole in a dose of 500 mg two times daily for the next 5 days. A Bio Gaya probiotic was added dur-
ing the 10-day treatment.
RESULTS: Hp-infection was successfully treated in 98 patients (94,2%) and in 79 out of 81 naive ones (97% 
of the cases). This therapy proved effective in 19 out of 23 patients (82,6%) after one or two failed Hp-infec-
tion eradications, too. The treatment failed in 6 patients (5,7%) because of a double antibiotic resistance.
CONCLUSION: The esomeprazole-based sequential therapy and Bio Gaya probiotic represented a highly 
and well-tolerable effective eradication option. Clinical symptoms and quality of life were favourable influ-
enced in all the patients as well as side effects were rare.
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INTRODUCTION
According to the Maastricht III Consensus 
Report (8), standard triple therapy (STT), double 
combination of clarithromycin and amoxicillin or 
metronidazole and proton pump inhibitor (PPI) 
for seven days are recommended and applied 
for Helicobacter pylori-infection (Hp-infection) 
eradication. Recent meta-analyses (7) show relatively 
low eradication rates following STT (less than 
80%). Hp antibiotic resistance mainly affects the 
effectiveness of eradication therapy (15) as eradication 
fails in 35-40% of the patients (15). 
Sequential eradication therapy has been 
introduced 10 years ago in Italy and nowadays 
represents an innovative approach making use 
of well-known and approved drugs against Hp-
infection. PPI exerts a direct antibacterial effect 
on Hp-infection (1) and creates favourable 
preconditions for the action of antibiotics thus being 
the basic component of eradication therapy. Second-
generation PPI enables an optimal pH control of 
gastric acid secretion and higher eradication levels 
(1,2). Elevation of omeprazole dosage of 20 mg up 
to 40 mg of esomeprazole twice daily increases the 
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Parameters/Values (n/%)
mean age (years) 54,5±15,7
gender (males/females) 58 (55,7)/42 (40,3)
smokers/non-smokers 48 (46,1)/56 (53,8)
patients’ aged over 70 years 21 (20,1)
examined dyspepsia  
(proved by fibrogastroscopy)
62 (59,6)





erosive antral gastritis 23 (22,1)
erythemic exudative gastritis 5 (4,8)
exacerbated antral gastritis 7 (6,7)
atrophic gastritis 5 (4,8)




histologic examination 72 (69,2)
urease test 85 (81,7)
fecal antigenic test 72 (69,2)
fecal polymerase chain reaction 15 (14,4)
urea breathing test 31 (29,8)
culture examination 8 (7,6)
naive patients 81 (77,8)
after one or two failed 
eradications
23 (22,1)
Table 1. Patients’ demographic and clinical characteristics 
(n=104)
rate of healing of acid-associated diseases by 8-12% 
(17). Supplementation of a probiotic improves the 
effectiveness and tolerability of the eradication 
regimen (3).
The aim of this study was to determine the 
therapeutic effect of the esomeprazole-based 
sequential eradication regimen in combination 
with a probiotic in some gastroduodenal diseases 
associated with Hp-infection.
MATERIAL AND METHODS
The study covered 104 patients with dominating 
upper dyspeptic syndrome (Table 1). Most of 
them were examined and monitored concerning 
Hp-infection by means of two or more methods. 
Esomeprazole-based sequential therapy consisted 
in amoxycillin in a dose of 1,0 g twice daily for 
the first five days followed by clarithromycin and 
metronidazole in a dose of 500 mg twice daily for 
the next 5 days. A Bio Gaya probiotic was added 
during the 10-day treatment. Esomeprazole was 
administered in a double dose of 40 mg twice daily. A 
Lactobacilus reuteri (Bio Gaya) probiotic was added 
in a dose of 1,0 g twice daily for 10 days. Culture 
examination with antibiotic testing was performed 
in eight patients, i.e. before treatment in two and after 
failed therapy in six patients. Repeatedly endoscopy 
was done in the patients with peptic ulcer disease, 
usually, on the 40th day after the initial examination 
as these with gastric ulcer were given esomeprazole 
in a dose of 40 mg daily. All the patients filled in a 
questionnaire about their individual quality of life, 
drug tolerance and side effects.
RESULTS
Our results were systematized on Table 2.
Hp-infection was successfully treated in 98 
patients (94,2%) and in 79 out of 81 naive ones 
(97% of the cases). This therapy proved effective 
in 19 out of 23 patients (82,6%) after one or two 
failed Hp-infection eradications, too. The treatment 
failed in 6 patients (5,7%) because of a double 
antibiotic resistance. Hp-infection was resistant to 
amoxicillin and clarithromycin in one patient and 
to clarithromycin and metronidazole in five patients. 
Hp-infection eradication was achieved in all the 
patients with peptic ulcer disease which correlated 
with ulcer epithelisation. Histomorphologically, 
there was a suppressed activity of gastritis and a 
restricted inflammatory infiltration. Eradication 
was achieved in 36 out of 42 patients (85%) with non-
ulcer dyspepsia. The therapy was successful in all the 
patients aged over 70 years as well as in 46 smokers 
and 52 non-smokers. Clinical symptoms were 
favourably influenced in 100% of the cases. Only two 
patients with failed eradication did not report any 
improvement of their quality of life. All the patients 
except one tolerated well the sequential eradication 
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mean age (years) 55/39 3/3
smokers/non-smokers 46/52 3/3
patients’ aged over 70 years 21 -
non-ulcer dyspepsia 36 6
peptic ulcer disease
   - duodenal ulcer with complete epithelization
   - duodenal ulcer with incomplete epithelization
   - gastric ulcer with complete epithelization










influenced clinical symptoms 98 6
naive patients 79 2
after one or two failed eradications 19 4
good quality of life 98 2
good tolerance 98 5
side effects 5 1
Table 2. Therapeutic results
therapy with a probiotic and presented with a good 
compliance. There were slight and rapidly transitory 
side effects in 6 patients only (5,7%) consisting in 
bitter regurgitations in four patients, nausea and 
constipation in one patient each. 
Two patients with failed eradication were naive 
and four ones had previously experienced one or 
two failed eradications. In all of them, the clinical 
symptoms were favourably influenced. Quality of life 
did not improve in two patients. A poor tolerance of 
the eradication regimen was shared by one patient. 
Only one patient complained of bitter regurgitations.
DISCUSSION
Our study confirms previous results about 
the higher effectiveness of sequential therapy in 
comparison with STT. Our eradication rate of 94,2% 
is similar to that of more than 98% reported in 
Italy (18). Our eradication rate in the naive patients 
is even of 97% that is similar to the results recently 
reported in Italy (6,12,20). The sequential regimen 
proves much more effective than STT (14) even in the 
patients with failed previous one or two eradications 
with suspected or identified clarithromycin 
resistance. Although our patients presented with an 
initial clarithromycin resistance we have performed 
a successful Hp-infection eradication in them. The 
failure is due to the double antibiotic resistance. 
Probably, the very high effectiveness of our sequential 
regimen results from the properly selected PPI, i. e. of 
nexium (esomeprazole). According to the Maastricht 
IV/Florence Consensus Report (9) there is indirect 
and direct evidence of the possible enhancement of 
the eradication through the higher PPI dosage (16) 
as well as of the better effect of the double PPI dosage 
than the single one.
A meta-analysis demonstrates that Hp 
eradication rate depends on PPI presence that 
on its part depends on CYP2C19 and MDR 
polymorphisms (10). Esomeprazole (nexium), in 
contrast to omeprazole, an extensive metabolizing 
agent, represents a metabolizer of predominant 
polymorphism enabling a high eradication rate (10). 
Esomeprazole possesses an excellent pharmacological 
and pharmacodynamics characteristic as it achieves 
an optimal long-lasting acid pH control and ensures 
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a better effect of antibiotics (13). Esomeprazole-based 
triple therapy is by 8% more effective than that with 
omeprazole although this difference is statistically 
insignificant (1,2). Data about the necessary duration 
of the treatment with esomeprazole and other PPIs 
are contradictory (1,4,13). The supplementation 
of Bio Gaya probiotic is of importance, too. 
Lactobacilus reuteri exerts a direct antibacterial 
effect on Hp. It colonizes gastric mucosa and 
reduces bacterial loading (3) thus potentiating 
the eradication. It seems promising to treat Hp-
infection with a probiotic combined with PPI thus 
eliminating the administration antibiotics and the 
antibiotic resistance as well. Probably, the probiotic 
influences on the tolerance to the eradication 
regimen and patient’s quality of life during and after 
the eradication and leads to minimization of the side 
effects.
In contrast to our data, several studies report a 
higher frequency of side effects, between 10 and 17% 
of the cases (14,20,21). Diarrhoea occurs most often, 
however, it is absent in our contingent at all, even in 
the age group over 70 years. The rapid and complete 
improvement of the clinical symptoms is, most likely, 
due to the probiotic and high dose of esomeprazole. 
The risk factors which are predictors of STT failure 
(11) do not exert any effect on the results from the 
sequential and eradication treatment. The advantage 
of the combination of a sequential regimen and 
probiotic consists in the fact that it is independent of 
the risk factors for STT failure such as clarithromycin 
resistance, tobacco smoking and non-ulcer 
dyspepsia. In the senile patients with eradicated Hp-
infection, there is epithelisation of the gastric and 
duodenal peptic ulcer and gastritis suppression as 
well. Similarly to other authors (5,19), we prove that 
this regimen should be recommended in patients 
with non-ulcer dyspepsia, too. 
CONCLUSION
The esomeprazole (nexium)-based sequential 
regimen combined with Bio Gaya probiotic 
represents a highly and well-tolerable effective 
eradication option for the patients with Hp-associated 
gastroduodenal diseases. It favourably influences on 
the clinical symptoms and patient’s quality of life. Its 
side effects are slight and rare. This ideal regimen 
should be recommended for the clinical practice.
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